IMPORTANT CAUTIONARY STATEMENT This presentation contains forward-looking statements. Investors are cautioned against placing undue reliance on these statements. All statements relating to events or results that may occu

WELCOME TO 2020 ANNUAL SHAREHOLDERS

MEETING NOVEMBER 20, 2020 Exhibit 99.1

IMPORTANT CAUTIONARY STATEMENT This

presentation contains forward-looking statements. Investors are cautioned against placing undue reliance on these statements. All statements relating to events or results that may occur in the future are forward-looking statements, including,

without limitation, statements regarding the following: the regulatory pathway for our products, including our existing and planned investigative new drug application and pre-market approval requirements, the timing, design and success of our

clinical trials and pursuit of biologic license applications ("BLAs") and other regulatory approvals for certain products; our expectations regarding our ability to continue marketing our micronized products and certain other products

during and following the end of the period of enforcement discretion announced by the United States Food and Drug Administration ("FDA"); expectations regarding future revenue growth, including product innovations, expansion into

additional domestic and international markets, our product pipeline and the potential to increase our product offerings, and future research and development expenses; ongoing and future effects arising from the COVID-19 pandemic and the

Company's plans to adhere to governmental recommendations with respect thereto; our expectations regarding market opportunities, expected growth in certain markets, and demographic and market trends.; and our expectations regarding our ability

to resolve certain legal matters. Forward-looking statements generally can be identified by words such as "expect," "will," "change," "intend," "seek," "target,"

"future," "plan," "continue," "potential," "possible," "could," "estimate," "may," "anticipate," "to be" and similar expressions.

These statements are based on numerous assumptions and involve known and unknown risks, uncertainties and other factors that could significantly affect the Company's operations and may cause the Company's actual actions, results,

financial condition, performance or achievements to differ materially. Factors that may cause such a difference include, without limitation, those discussed under the heading "Risk Factors" in our most recent Form 10-Q and in our Form

10-K for the year ended December 31, 2019. Unless required by law, the Company does not intend, and undertakes no obligation, to update or publicly release any revision to any forward-looking statements, whether as a result of the receipt of new

information, the occurrence of subsequent events, a change in circumstances or otherwise. Each forward-looking statement contained herein is specifically qualified in its entirety by the aforementioned factors.

MEETING AGENDA Introductions Annual

Meeting Matters Company Highlights Commercial Research & Development Question & Answer Session 1 2 3 4 5 6

ANNUAL MEETING MATTERS

ANNUAL MEETING AGENDA QUORUM

DESCRIPTION OF BUSINESS ITEMS: Election of Two Class I Directors Approval of Amendment to Charter to Increase the Number of Authorized Shares of Common Stock Approval of Amendments to the Company's 2016 Equity and Cash Incentive Plan OPENING

OF POLLS FOR VOTING CLOSING OF POLLS REPORT ON RESULTS OF VOTE ADJOURNMENT COMPANY PRESENTATION QUESTION & ANSWER SESSION 1 2 3 4 5 6 7 8

PATIENTS ARE WHY WE ARE HERE. WE HAVE

AN OPPORTUNITY AND RESPONSIBILITY TO MAKE A DIFFERENCE FOR THESE PATIENTS. AND IN DOING SO, GROW A SUCCESSFUL AND MEANINGFUL HEALTHCARE COMPANY." " TIMOTHY R. WRIGHT CHIEF EXECUTIVE OFFICER ALVIN PHYLLIS NICK RUTH

MIMEDX IS A PIONEER IN PLACENTAL

BIOLOGICS Leading Brands in Existing Core Business Position Company to Capitalize on Late-stage Pipeline Business now positioned for sustainable & profitable growth Existing Core Business Late-Stage Pipeline Market opportunity Clinical evidence

MIMEDX IS A PIONEER IN PLACENTAL

BIOLOGICS Market Opportunity 17.5M Patients1 Clinical Evidence Target Product Profile Commercialization Strategy Existing Core Business Late-Stage Pipeline (1) Global Data Knee Reconstruction Data Model United States 2020 Business now positioned for

sustainable & profitable growth

Offers non-surgical treatment option

to reduce pain & improve function INCREASING OPTIMISM IN KNEE OA OPPORTUNITY (1) Knee Osteoarthritis; Global Data Knee Reconstruction Data Model United States 2020; (2) 2014 IQVIA Claims data with 2% growth rate; (3) Bannuru RR, Brodie CR,

Sullivan MC, McAlindon TE. Safety of Repeated Injections of Sodium Hyaluronate (SUPARTZ) for Knee Osteoarthritis: A Systematic Review and Meta-Analysis. Cartilage. 2016;7(4):322-332. doi:10.1177/1947603516642271; Management Estimates based on

at least two injections per patient; (4) Knee OA Primary Research/Conjoint Analysis (n=182) performed by Market Vision December 2019 https://www.mv-research.com/ (data on file); Management estimates Informed by low dropout rate, additional dosing

potential in Phase 2B clinical trial, and evolving competitive landscape ~1M-1.5M

THREE PRIMARY DOMAINS OF VALUE

CREATION Operations Commercial R&D Core business investment drives sustainable growth and creates competitive advantage

Existing Core Business Drive disease

state awareness across care continuum Publish additional data Expand into additional wound applications FOUR KEY DRIVERS TO ACHIEVE CORE GROWTH Portfolio Expansion Advance market assessments and analytics Leverage clinical and regulatory expertise

Invest in prioritized new markets Maximize core business Enhance sales force productivity and commercial analytics Highlight clinical and economic value Continue product innovation Explore additional priority markets Identify wound care adjacencies

PURSUE INTERNATIONAL EXPANSION ENHANCE PORTFOLIO VALUE TARGET NEW BUSINESS EXPAND THE MARKET 2 1 3 4

6% CAGR $1B skin substitutes

AMNIOTIC TISSUE: LARGEST & FASTEST GROWING SEGMENT OF SKIN/DERMAL SUBSTITUTE MARKET Amniotic Tissue Allografts Xenograft Skin Substitutes ~$233M Others +8-10% CAGR U.S. Amniotic Tissue Market Source: BioMed GPS SmartTrak; CAGR 2019-2024E

Competitor A Others Competitor B Competitor C Aging population Growing prevalence of diabetes and chronic wounds Increasing number of wound care procedures Rising physician awareness of new treatment options Focus on clinical efficacy and cost

effectiveness Growth drivers:

Existing Core Business MAXIMIZING

OPPORTUNITIES IN OUR CORE BUSINESS 2 1 3 Increase Market Opportunity Capture Disproportionate Share Invest to Enhance Commercial Excellence Model

STRATEGIES TACTICS Raise Patient

Awareness Enhance Provider Engagement Leverage New Products Direct-to-patient initiatives Quality medical education for 1,500+ HCPs Leverage treatment options throughout care continuum 1 INCREASE MARKET OPPORTUNITY new!

CAPTURE DISPROPORTIONATE SHARE

STRATEGIES TACTICS Communicate Product Differentiation Build Provider Confidence Build Payor Confidence Proprietary process More than 2 million allografts AHRQ data1,2 Generate health economic data Prove value to total cost of care Expand coverage

to additional areas of use 2 (1) Agency for Healthcare Research and Quality (AHRQ); (2) Skin Substitutes for Treating Chronic Wounds Technical Brief; Technology Assessment Program; Agency for Healthcare Research and Quality, Feb 2, 2020

Reimbursement coverage, U.S. 300M+ lives

3 INVEST TO ENHANCE COMMERCIAL

EXCELLENCE MODEL TACTICS Identify, Target, Educate Demand Generation Fulfillment Build Analytics and Customer Segmentation Target high value customers Education programs that drive awareness & utilization Expand Sales Team by 10%+ Near-term

investment in structure and scale Improve productivity by targeting and training Promote Value-added support Insurance verification teams process >50,000 patients/yr Reimbursement education to improve customer efficiency 4,000+ accounts 2,500+

physicians CUSTOMER ECOSYSTEM STRATEGIES

Existing Core Business Pipeline

R&D STRATEGIC IMPERATIVES "361" pathway "Minimally manipulated" and "Homologous Use" Current Good Tissue Practices (CGTP) Requires FDA review "351" pathway More than "minimally

manipulated" and/or "non-homologous use" Current Good Manufacturing Practices (CGMP) Requires FDA pre-market approval for specific indications of use ADVANCE TIMELINE TO BLA GROW CORE BUSINESS PROTECT EXISTING AREAS OF USE PRODUCT

INNOVATION Regulatory Pathway Requires Different Development Approaches

PHASE 2B STUDY DEMONSTRATES

SIGNIFICANT BENEFIT Primary Efficacy Endpoint: reduction in VAS (visual analog scale) score for pain (p<0.0001) Secondary Efficacy Endpoint: improvement in FFI-R (Foot Function Index-Revised) score (p=0.0004) At 3-month follow-up visit, average

reduction VAS score for pain was 76% vs. 45% for Control 0% -10% -20% -30% -40% -50% -60% -70% -80% -90% -100% Reduction from Baseline Day 0 Month 1 Month 2 Month 3 Month 6 Month 12 At 3 months, subjects in placebo group were allowed to undergo

alternative therapy AmnioFix Saline

PLANTAR FASCIITIS (PF) CURRENT

STATUS Phase 2B study completed Phase 3 study enrollment completed 277 patients in September 2020 Last patient out in Q2 2021 Potential timeline* Meeting with FDA mid-2021 BLA filing 1H 2022 FDA approval and product launch 1H 2023 PF Study Informs

Safety, Efficacy and Other Future Indications Plantar Fasciitis 1H 2H 1H 2H 1H 2H 1H 2H 2020 2021 2022 2023 PH3 Est. BLA Filing Est. BLA Approval * Timeline represents current plans and estimates only. Actual results and timing may differ

materially. There can be no assurance that clinical trials are conducted or completed on schedule, that trial results are favorable, or that we obtain regulatory approval for our products and indications.

RESULTS OF RETROSPECTIVE STUDY BY

DR. KRIS ALDEN INDICATE SIGNIFICANT BENEFIT FROM mdHACM INJECTIONS Source: Alden KJ, Harris S, Hubbs B, Kot K, Istwan NB, Mason D. Micronized Dehydrated Human Amnion Chorion Membrane Injection in the Treatment of Knee Osteoarthritis-A Large

Retrospective Case Series [published online ahead of print, 2019 Nov 28]. J Knee Surg. 2019;10.1055/s-0039-3400951. doi:10.1055/s-0039-3400951.

Knee Osteoarthritis 1H 2H 1H 2H 1H

2H 1H 2H 1H 2H 1H 2H 2021 2022 2023 2024 2025 2026 KNEE OSTEOARTHRITIS (OA) CURRENT STATUS Phase 2B study ongoing Enrollment completed September 2020 Completed early, despite COVID-19 challenges 447 patients enrolled Drop-out rates lower than

expected - 3% actual compared to 10% anticipated Last Patient Out for 6-month blinded observation in late 2021 6-month open-label extension allows all patients option to receive mdHACM Potential timeline* Meeting with FDA in mid-2021 Phase 3

initiation in first half 2022 BLA filing 2H 2024 / 1H 2025 FDA approval and product launch in 2H 2025 / 1H 2026 Critical success factors Advantaged by CGMP readiness for Plantar Fasciitis BLA RMAT designation provides frequent dialogue with the FDA

FDA meeting Phase 3 initiation Est. launch PH2 PH3 Est. BLA Filing * Timeline represents current plans and estimates only. Actual results and timing may differ materially. There can be no assurance that clinical trials are conducted or completed on

schedule, that trial results are favorable, or that we obtain regulatory approval for our products and indications

2020 2021 2022 2023 2024 2025 1H 2H 1H

2H 1H 2H 1H 2H 1H 2H 1H 2H INJECTABLE AMNION-CHORION Plantar Fasciitis Achilles Tendonitis Knee Osteoarthritis BLA APPROVAL REQUIRES CMC+CGMP+RCTs PHASE 3 PHASE 2 PHASE 3 LPI LPO LPI LPO 25 LPI = last patient in LPO = last patient out End of

Enforcement Discretion Estimated BLA Filing Estimated BLA Approval BLA Filing dependent on data readout CMC = Chemistry, Manufacturing and Controls; CGMP = Current Good Manufacturing Practices; RCT = Randomized Controlled Trial; According to

recently updated FDA guidance, FDA generally intends to exercise enforcement discretion through May 31, 2021, with respect to the IND and the premarket approval requirements for certain HCT/Ps, provided that use of the HCT/P does not raise reported

safety concerns or potential significant safety concerns.; Timeline represents current plans and estimates only. Actual results and timing may differ materially. There can be no assurance that clinical trials are conducted or completed on schedule,

that trial results are favorable, or that we obtain regulatory approval for our products and indications PHASE 3 LPI LPO Synergistic activities across both indications help contribute to overall BLA program

MIMEDX IS A PIONEER IN PLACENTAL

BIOLOGICS Core business investment drives sustainable growth and creates competitive advantage Existing Core Business Late-Stage Pipeline Market opportunity Clinical evidence Commercialization Business now positioned for sustainable & profitable

REGULATORY ENVIRONMENT OVERVIEW 361

351 Human Tissue (i.e., placental tissue) When minimally manipulated When more than minimally manipulated Indication for use Homologous use* As indicated by clinical trial Manufacturing process cGTP cGMP FDA Oversight Regulated by the FDA for risk

of disease transmission Approved by the FDA for a specific indication for use * Homologous use means that the donated tissue serves the same basic function in a recipient as the tissue as in the donor Enforcement Discretion: According to recently

updated FDA guidance, FDA generally intends to exercise enforcement discretion through May 31, 2021, with respect to the IND and the premarket approval requirements for certain HCT/Ps, provided that use of the HCT/P does not raise reported safety

concerns or potential significant safety concerns.

PHASE 2B STUDY DEMONSTRATES

SIGNIFICANT BENEFIT Plantar Fasciitis (PF) Phase 2b Study, AIPF004 147, subjects randomized, 100.68% complete enrollment Total number of sites: 14 Study closed to enrollment, 12-month efficacy endpoint completed, study closeout visits completed

Final site monitoring visit completed August 14, 2018 Timetable for Analysis and Clinical Study Report: Clinical Study Report for Phase 2B Plantar Fasciitis trial in development. Final draft of data tables reviewed with statistics group and final

analytical data tables received by Clinical. These have been sent to Rho. Completion of the Clinical Study Report initiated and hope to complete and audit HPA by Dec 2020. "End of Phase 2 Meeting" - MiMedx met with FDA in April 2017 Face

to Face Meeting Presented Interim (3 month) Phase 2B data Presented Phase 3 Protocol and discussed FDA had no comments about clinical study, Phase 3 Initiated Since Phase 2 data were "interim" this was not labeled a formal End of Phase

meeting, but served that purpose. Next planned meeting as per regulations is Pre-BLA submission Primary Efficacy Endpoint: reduction in VAS (visual analog scale) score for pain (p<0.0001) Secondary Efficacy Endpoint: improvement in FFI-R (Foot

Function Index-Revised) score (p=0.0004) At 3-mo. follow-up visit, average reduction VAS score for pain was 76% vs. 45% for Control Per Protocol Analysis: 135 subjects LOCF Pooled Site analysis dataset: Completed LOCF Original Site: Completed

Observed Case Pooled Site: Completed Observed Case Original Site: Completed Clinical Study Report (CSR): Date to be revised Manuscript: estimated submission for publication Q1 2021

INJECTABLE DEHYDRATED HUMAN

AMNION/CHORION MEMBRANE (dHACM) IN THE TREATMENT OF KNEE OSTEOARTHRITIS Methods Conclusions To our knowledge, these data represents the largest single-physician experience with injectable amniotic tissue in the treatment of knee OA to date. In our

experience, injectable dHACM appears to be a potentially useful treatment option for patients with knee OA. Further controlled studies are required to confirm these observations. Data from 82 patients with 100 treated knees were included for